专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007062488A1 PERSONAL TRANSMITTER/RECEIVER 审中-公开
标题翻译：个人发射器/接收器
公开(公告)号：WO2007062488A1
公开(公告)日：2007-06-07
申请号：PCT/AU2006/001839
申请日：2006-12-04
申请人： JANSSON, Karl, Erik , PASIC, Najdan
发明人： JANSSON, Karl, Erik , PASIC, Najdan
IPC分类号： H04Q7/20 , G06T13/00 , G06F15/16 , G06T15/70
CPC分类号： G06Q10/10 , G06Q30/02 , G08B2001/085 , H04L67/18 , H04L67/306 , H04W8/18
摘要： Disclosed herein is a personal transmitter/receiver (100) that includes a processor (110), a power source (130), a phone communications module (120), an optional display module (140), a manual control module (150), an ad-hoc radio network module (160), a body sensing timeout module (170), and a warning device (170). The personal transmitter/receiver device (100) is preferably a portable unit worn by a user, wherein the personal transmitter/receiver device is adaptable to be worn in a concealed manner beneath an outer layer of clothing. The ad-hoc radio network module (160) includes a wireless transceiver unit for establishing a communications link with a proximally located second transmitter/receiver associated with another user.
摘要翻译：本文公开了一种个人发送器/接收器（100），其包括处理器（110），电源（130），电话通信模块（120），可选显示模块（140），手动控制模块（150）自组织无线电网络模块（160），身体感测超时模块（170）和警告装置（170）。个人发射机/接收机设备（100）优选地是由用户佩戴的便携式单元，其中个人发射机/接收机设备适于以隐蔽的方式佩戴在外层衣服之下。所述自组织无线电网络模块（160）包括无线收发器单元，用于与与其他用户相关联的近端定位的第二发射机/接收机建立通信链路。

2. 发明申请

WO2014153145A3 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF 审中-公开
标题翻译： LAQUINIMOD SODIUM水晶及其制造方法改进
公开(公告)号：WO2014153145A3
公开(公告)日：2015-04-23
申请号：PCT/US2014029292
申请日：2014-03-14
申请人： TEVA PHARMA , TEVA PHARMA , FRENKEL ANTON , LAXER AVITAL , IOFFE VLADIMIR , JANSSON KARL-ERIK , FRISTEDT ULF TOMAS
发明人： FRENKEL ANTON , LAXER AVITAL , IOFFE VLADIMIR , JANSSON KARL-ERIK , FRISTEDT ULF TOMAS
IPC分类号： C07D215/56
CPC分类号： C07D215/56 , A61K31/47 , C07B2200/13 , G01N30/06 , G01N33/15
摘要： The present application provides subject-matter related to a mixture of crystalline laquinimod sodium particles, wherein (i) > 90% of the total amount by volume of the laquinimod sodium particles have a size of 50% of the total amount by volume of the laquinimod sodium particles have a size of
摘要翻译：本申请提供了与结晶laquinimod钠颗粒的混合物相关的主题，其中（i）拉喹莫德钠颗粒的总体积的90％具有<40微米的尺寸或（ii）> 50％的拉喹莫德钠颗粒的总体积量具有<15μm的尺寸，并且其中关于堆积密度，抽头密度和某些杂质的量满足一个或多个进一步的要求。本申请还提供了包含一定量的拉喹莫德和BH-3-HLAQ，MCQ，MCQCA，MCQME，NEA和MCQEE中的至少一种的药物组合物。本发明还提供制备BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE和由所述方法制备的化合物的方法。还提供了一种用于测试拉喹莫德样品是否含有不期望的杂质的方法。还提供了（a）制备包含拉喹莫德的经验证的药物组合物的方法，（b）分发经验证的药物组合物包含拉喹莫德，（c）验证一批含有拉喹莫德的药物产品，（d）制备包装的药物组合物包含拉喹莫德，其各自包括测定样品或批次中BH-3-HLAQ，MCQ，MCQCA，MCQME，NEA和MCQEE中的至少一种的量。本发明还提供使用BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE作为参考标准，以检测包含拉喹莫德的药物组合物中痕量的杂质。最后，本发明提供了在包含laquinimod的药物组合物中确定BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE，5-HLAQ，SPIRO-LAQ或3-H-LAQ的浓度的方法。

3. 发明申请

WO2014153145A2 CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF 审中-公开
标题翻译： LAQUINIMOD SODIUM水晶及其制造方法改进
公开(公告)号：WO2014153145A2
公开(公告)日：2014-09-25
申请号：PCT/US2014/029292
申请日：2014-03-14
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , FRENKEL, Anton , LAXER, Avital , IOFFE, Vladimir , JANSSON, Karl-Erik , FRISTEDT, Ulf, Tomas
发明人： FRENKEL, Anton , LAXER, Avital , IOFFE, Vladimir , JANSSON, Karl-Erik , FRISTEDT, Ulf, Tomas
CPC分类号： C07D215/56 , A61K31/47 , C07B2200/13 , G01N30/06 , G01N33/15
摘要： The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) ≥ 90% of the total amount by volume of the laquinimod sodium particles have a size of ≤ 40 μm or (ii) ≥ 50% of the total amount by volume of the laquinimod sodium particles have a size of ≤ 15 μm, and wherein: a) the mixture has a bulk density of 0.2-0.4 g/mL; b) the mixture has a tapped density of 0.40-0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 20ppm relative to the amount by weight of laquinimod sodium; d) an amount of MCQ in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of MCQCA in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; or f) an amount of MCQME in the mixture is no more than 0.12% relative to the amount of laquinimod sodium as measured by HPLC. The subject invention also provides a pharmaceutical composition comprising an amount of laquinimod and at least one of BH-3-HLAQ, MCQ, MCQCA, MCQME, NEA, and MCQEE. The subject invention also provides processes for preparing BH-3-HLAQ, MCQ, MCQCA, MCQME, MCQEE, and compounds prepared by said processes. Further provided is a process for testing whether a sample of laquinimod contains an undesirable impurity. Further provided isp a process for preparing a validated pharmaceutical composition comprising laquinimod, for preparing a pharmaceutical composition comprising laquinimod, or for distributing a validated batch of a pharmaceutical composition comprising laquinimod, for validating a batch of a pharmaceutical product containing laquinimod and a pharmaceutically acceptable carrier for distribution, and for preparing a packaged pharmaceutical composition comprising laquinimod, each comprising determining the amount of at least one of BH-3-HLAQ, MCQ, MCQCA, MCQME, NEA, and MCQEE in a sample or batch. The subject invention further provides use of BH-3-HLAQ, MCQ, MCQCA, MCQME, MCQEE as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising laquinimod. Finally, the subject invention provides methods of ddenrrining the concentration of BH-3- HLAQ, MCQ, MCQCA, MCQME, MCQEE, 5-HLAQ, SPIRO-LAQ or 3 H-LAQ in a pharmaceutical composition comprising laquinimod.
摘要翻译：本发明提供结晶laquinimod钠颗粒的混合物，其中（i）拉喹莫德钠颗粒的总体积的≥90％具有≤40μm的尺寸或（ii）≥体积总量的50％的拉喹莫德钠颗粒的尺寸为≤15μm，其中：a）混合物的堆积密度为0.2-0.4g / mL; b）混合物的敲击密度为0.40-0.7g / mL; c）相对于拉喹莫德钠的重量，混合物中的重金属量不超过20ppm; d）混合物中MCQ的量相对于通过HPLC测量的拉喹莫德钠的量不超过0.15％; e）混合物中MCQCA的量相对于通过HPLC测量的拉喹莫德钠的量不超过0.15％; 或f）混合物中MCQME的量相对于通过HPLC测量的拉喹莫德钠的量不超过0.12％。本发明还提供了包含一定量的拉喹莫德和BH-3-HLAQ，MCQ，MCQCA，MCQME，NEA和MCQEE中的至少一种的药物组合物。本发明还提供制备BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE和由所述方法制备的化合物的方法。还提供了一种用于测试拉喹莫德样品是否含有不期望的杂质的方法。进一步提供的isp是制备包含laquinimod的经验证的药物组合物的方法，用于制备包含laquinimod的药物组合物或用于分配经验证的批次的包含laquinimod的药物组合物，用于验证一批含有laquinimod的药物产品和药学上可接受的载体用于分配和用于制备包含拉喹莫德的包装药物组合物，每种包含确定样品或批次中BH-3-HLAQ，MCQ，MCQCA，MCQME，NEA和MCQEE中的至少一种的量。本发明还提供使用BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE作为参考标准，以检测包含拉喹莫德的药物组合物中痕量的杂质。最后，本发明提供了包含laquinimod的药物组合物中BH-3-HLAQ，MCQ，MCQCA，MCQME，MCQEE，5-HLAQ，SPIRO-LAQ或3-H-LAQ的浓度的方法。

4. 发明申请

WO2012004338A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES 审中-公开
标题翻译：制备喹啉-3-羧酰胺的方法
公开(公告)号：WO2012004338A1
公开(公告)日：2012-01-12
申请号：PCT/EP2011/061490
申请日：2011-07-07
申请人： ACTIVE BIOTECH AB , BOCK, Lillemor Maria , HOLMBERG, Pär Henning , JANSSON, Karl-Erik
发明人： BOCK, Lillemor Maria , HOLMBERG, Pär Henning , JANSSON, Karl-Erik
IPC分类号： C07D215/56
CPC分类号： C07D215/56
摘要： A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191 °C; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture.
摘要翻译：通过使适当的烷基酯和苯胺衍生物在含有沸点在68-191℃的脂族溶剂或脂族溶剂的混合物的回流混合物中制备式（I）化合物的方法; 冷凝回流混合物的蒸气; 用醇清除剂或酒精清除剂的混合物处理冷凝的蒸气; 并将冷凝的蒸汽返回到反应混合物中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式